Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

被引:7
|
作者
Virseda-Berdices, Ana [1 ,2 ]
Rojo, David [3 ]
Martinez, Isidoro [1 ,2 ]
Berenguer, Juan [2 ,4 ,5 ]
Gonzalez-Garcia, Juan [2 ,6 ,7 ]
Brochado-Kith, Oscar [1 ,2 ]
Fernandez-Rodriguez, Amanda [1 ,2 ]
Diez, Cristina [2 ,4 ,5 ]
Hontanon, Victor [2 ,6 ,7 ]
Perez-Latorre, Leire [2 ,4 ,5 ]
Mican, Rafael [2 ,6 ,7 ]
Barbas, Coral [3 ]
Resino, Salvador [1 ,2 ]
Jimenez-Sousa, Maria Angeles [1 ,2 ]
机构
[1] Inst Salud Carlos III ISCIII, Ctr Nacl Microbiol CNM, Unidad Infecc Viral & Inmunidad, Madrid, Spain
[2] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas, Madrid, Spain
[3] Univ CEU San Pablo, Fac Farm, Dept Quim & Bioquim, Ctr Metab & Bioanal CEMBIO,Urbanizac Monteprincip, Madrid 28925, Spain
[4] Hosp Gen Univ Gregorio Maranon, Unidad Enfermedades Infecciosas VIH, Madrid, Spain
[5] Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
[6] Hosp Univ La Paz, Serv Med Interna Unidad VIH, Madrid, Spain
[7] Inst Invest Sanitaria La Paz IdiPAZ, Madrid, Spain
关键词
Chronic hepatitis C; HIV; Cirrhosis; Metabolomics; DAAs therapy; HCV elimination; HUMAN-IMMUNODEFICIENCY-VIRUS; AMINO-ACID GRANULES; EVENT-FREE SURVIVAL; HEPATITIS-C; LIVER-DISEASE; HEPATOCELLULAR-CARCINOMA; PROGRESSION; SOFOSBUVIR; FIBROSIS;
D O I
10.1016/j.biopha.2022.112623
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: A better understanding of the evolution of cirrhosis after hepatitis C virus (HCV) clearance is essential since the reversal of liver injury may not happen. We aimed to assess the evolution of plasma metabolites after direct-acting antivirals (DAAs) therapy and their association with liver disease scores in HIV/HCV-coinfected patients with advanced HCV-related cirrhosis. Methods: We performed a prospective study in 49 cirrhotic patients who started DAAs therapy. Data and samples were collected at baseline and 36 weeks after SVR. Metabolomics analysis was carried out using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Inflammation-related biomarkers were analyzed using ProcartaPlex Immunoassays. Results: At 36 weeks after SVR, patients experienced significant decrease in taurocholic acid, 2,3-butanediol, and LPC(18:0); while several phosphatidylcholines (LPC(16:1), LPC(18:1), LPC(20:4), and PC(16:0/9:0(CHO))/PC (16:0/9:0(COH)), 2-keto-n-caproic acid/2-keto-isocaproic acid and N-methyl alanine increased, compared to baseline. The plasma decrease in taurocholic acid was associated with a reduction in Child-Turcotte-Pugh (CTP) (AMR-3.39; q-value=0.006) and liver stiffness measurement (LSM) (AMR-1.06; q-value<0.001), the plasma increase in LPC(20:4) was related to a reduction in LSM (AMR-0.98; q-value=0.027), and the rise of plasma 2-keto-n-caproic acid/2-keto-isocaproic acid was associated with a reduction in CTP (AMR-0.35; q-value=0.004). Finally, plasma changes in taurocholic acid were directly associated with inflammation-related biomarkers, while changes in LPC(20:4) were inversely associated. Conclusions: Plasma metabolomic profile changed after HCV clearance with all oral-DAAs in HIV/HCV-coinfected with advanced HCV-related cirrhosis. Changes in plasma levels of LPC (20: 4), 2-keto-n-caproic acid/2-keto-isocaproic acid, and taurocholic acid were related to improvements in cirrhosis scores and inflammatory status of patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients
    Salguero, Sergio
    Rojo, David
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Fernandez-Rodriguez, Amanda
    Brochado-Kith, Oscar
    Diez, Cristina
    Hontanon, Victor
    Virseda-Berdices, Ana
    Martinez, Javier
    Ibanez-Samaniego, Luis
    Llop-Herrera, Elba
    Barbas, Coral
    Resino, Salvador
    Jimenez-Sousa, Maria A.
    LIVER INTERNATIONAL, 2020, 40 (09) : 2215 - 2227
  • [2] Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response
    Luis Casado, Jose
    Angeles Esteban, Maria
    Banon, Sara
    Moreno, Ana
    Perez-Elias, Maria J.
    Luisa Mateos, Maria
    Moreno, Santiago
    Quereda, Carmen
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (11) : 3473 - 3481
  • [3] Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
    Perez-Latorre, Leire
    Sanchez-Conde, Matilde
    Miralles, Pilar
    Carlos Lopez, Juan
    Parras, Francisco
    Tejerina, Francisco
    Aldamiz-Echevarria, Teresa
    Carrero, Ana
    Diez, Cristina
    Ramirez, Margarita
    Gutierrez, Isabel
    Maria Bellon, Jose
    Banares, Rafael
    Berenguer, Juan
    BMC INFECTIOUS DISEASES, 2018, 18
  • [4] Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy
    Labarga, P.
    Fernandez-Montero, J. V.
    Barreiro, P.
    Pinilla, J.
    Vispo, E.
    de Mendoza, C.
    Plaza, Z.
    Soriano, V.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 (07) : 475 - 479
  • [5] Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals
    Molina-Carrion, Silvia
    Brochado-Kith, Oscar
    Gonzalez-Garcia, Juan
    Berenguer, Juan
    Diez, Cristina
    Llop, Elba
    Hontanon, Victor
    Ibanez-Samaniego, Luis
    Luisa Montes, Maria
    Resino, Salvador
    Fernandez-Rodriguez, Amanda
    Angeles Jimenez-Sousa, Maria
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (08) : 1 - 13
  • [6] Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
    Medrano, Luz Maria
    Berenguer, Juan
    Salguero, Sergio
    Gonzalez-Garcia, Juan
    Diez, Cristina
    Hontanon, Victor
    Garcia-Broncano, Pilar
    Ibanez-Samaniego, Luis
    Bellon, Jose M.
    Jimenez-Sousa, Maria Angeles
    Resino, Salvador
    FRONTIERS IN MEDICINE, 2021, 8
  • [7] Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients
    Virseda-Berdices, Ana
    Martin-Escolano, Ruben
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Brochado-Kith, Oscar
    Rojo, David
    Diez, Cristina
    Hontanon, Victor
    Perez-Latorre, Leire
    Ibanez-Samaniego, Luis
    Llop-Herrera, Elba
    Olveira, Antonio
    Fernandez-Rodriguez, Amanda
    Barbas, Coral
    Resino, Salvador
    Jimenez-Sousa, Maria angeles
    ESCORIAL Study Grp
    LIVER INTERNATIONAL, 2025, 45 (01)
  • [8] High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients
    Smolders, Elise J.
    Smit, Colette
    de Kanter, Clara T. M. M.
    Dofferiiof, Anton S. M.
    Arends, Joop E.
    Brinkman, Kees
    Rijnders, Bart
    van der Valk, Marc
    Reiss, Peter
    Burger, David M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 76 (02) : 193 - 199
  • [9] Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases
    Righi, E.
    Londero, A.
    Pea, F.
    Bonora, S.
    Nasta, P.
    Della Siega, P.
    Delle Foglie, P.
    Villa, G.
    Giglio, O.
    Dal Zoppo, S.
    Baccarani, U.
    Bassetti, M.
    TRANSPLANT INFECTIOUS DISEASE, 2015, 17 (01) : 147 - 153
  • [10] HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe
    Amele, Sarah
    Sandri, Anastasia Karachalia
    Rodger, Alison
    Vandekerckhove, Linos
    Benfield, Thomas
    Milinkovic, Ana
    Duvivier, Claudine
    Stellbrink, Hans-Jurgen
    Sambatakou, Helen
    Chkhartishvili, Nikoloz
    Caldeira, Luis
    Laguno, Monserrat
    Domingo, Pere
    Wandeler, Gilles
    Gisinger, Martin
    Kuzovatova, Elena
    Dragovic, Gordana
    Knysz, Brygida
    Matulionyte, Raimonda
    Rockstroh, Jurgen Kurt
    Lundgren, Jens Dilling
    Mocroft, Amanda
    Peters, Lars
    HIV MEDICINE, 2022, 23 (06) : 684 - 692